iRhythm Technologies (NASDAQ:IRTC) Releases Quarterly Earnings Results, Beats Estimates By $0.31 EPS

iRhythm Technologies (NASDAQ:IRTC) released its earnings results on Thursday. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.66) by $0.31, FiscalAI reports. The firm had revenue of $199.39 million for the quarter, compared to the consensus estimate of $194.11 million. iRhythm Technologies had a negative return on equity of 28.15% and a negative net margin of 5.96%.The company’s revenue for the quarter was up 25.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.97) EPS.

Here are the key takeaways from iRhythm Technologies’ conference call:

• Strong Q1 financials — revenue of $199.4M (+25.7% YoY), adjusted EBITDA margin 7.1% (up 880 bps), raised 2026 revenue guide to $875–$885M and adjusted EBITDA margin to 12–13%, with ~$549.6M in cash and marketable securities.
• Broad commercial momentum across Zio Monitor and Zio AT, with expansion upstream into primary care (now a meaningful share of volume), 53% of volume via EHR integrations, and new-store growth accounting for ~64% of year?over?year volume gains.
• Product and AI roadmap progressing — next?generation AI 510(k) submitted and expected approval later this year, Zio MCT release reaffirmed for H1 2027, and the AI is expected to cut technician review time by ~50% and drive material margin/efficiency gains across the platform.
• Regulatory and legal uncertainty remains — an FDA warning letter is still open despite remediation and a third?party review with no material findings, the DOJ CID (focused on historical Zio AT periods) remains active, and the final CMS/MAC LCD outcome is uncertain.
• International and adjacent market expansion is early — U.K. posted the company’s best quarter, Japan received a modest supplemental reimbursement (not yet meaningful), and sleep pilots are encouraging but unlikely to move the needle materially before 2027.

iRhythm Technologies Trading Down 6.5%

iRhythm Technologies stock traded down $8.40 during mid-day trading on Friday, hitting $120.76. The company’s stock had a trading volume of 1,069,730 shares, compared to its average volume of 629,176. The company has a 50 day moving average of $122.93 and a 200-day moving average of $154.60. The stock has a market cap of $3.97 billion, a PE ratio of -86.26 and a beta of 1.18. The company has a debt-to-equity ratio of 4.25, a quick ratio of 4.48 and a current ratio of 4.63. iRhythm Technologies has a one year low of $112.31 and a one year high of $212.00.

Analysts Set New Price Targets

Several research firms have recently weighed in on IRTC. The Goldman Sachs Group cut their target price on iRhythm Technologies from $184.00 to $147.00 and set a “neutral” rating on the stock in a research report on Thursday, April 9th. Morgan Stanley reissued an “overweight” rating on shares of iRhythm Technologies in a research report on Monday, January 12th. Canaccord Genuity Group cut their target price on iRhythm Technologies from $212.00 to $198.00 and set a “buy” rating on the stock in a research report on Friday, February 20th. Freedom Capital raised iRhythm Technologies to a “strong-buy” rating in a research report on Thursday, January 15th. Finally, Wells Fargo & Company cut their price objective on iRhythm Technologies from $200.00 to $180.00 and set an “overweight” rating on the stock in a research report on Friday. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $199.15.

More iRhythm Technologies News

Here are the key news stories impacting iRhythm Technologies this week:

• Positive Sentiment: Q1 results beat expectations — Revenue of $199.4M (+25.6% YoY) and adjusted loss per share of $0.35 topped estimates, showing meaningful top?line growth and an improving EPS trend. This underpins continued adoption of iRhythm’s diagnostic service. Read More.
• Positive Sentiment: Needham raised its price target to $255 and maintains a Buy — a bullish analyst signal that implies substantial upside and supports a longer?term growth narrative. Read More.
• Positive Sentiment: Street commentary highlights the quarter as a rebound: coverage notes the revenue and loss improvement vs. prior year, which can support multiple expansion if margins continue to improve. Read More.
• Neutral Sentiment: FY2026 revenue guidance was issued roughly in line with consensus (~$875–885M vs. $876M street est.), which removes the upside surprise element and leaves investors focused on margin/cost trajectory. Read More.
• Neutral Sentiment: Management commentary and the full earnings call transcript provide more color on adoption, margin improvement and investments in AI/regulatory work — important for medium?term thesis but not immediately catalytic. Read More.
• Neutral Sentiment: Analyst/market deep dives highlight market expansion and AI/regulatory developments as potential long?term positives; these are thematic and may take time to move the stock. Read More.
• Negative Sentiment: Wells Fargo cut its price target from $200 to $180 (still Overweight), which may signal more cautious near?term outlook from some investors and contributed to selling pressure. Read More.
• Negative Sentiment: Truist reduced its price target ahead of the quarter, another headwind that can weigh on sentiment and short?term flows. Read More.

Insider Buying and Selling

In other iRhythm Technologies news, EVP Minang Turakhia sold 7,804 shares of the company’s stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $135.42, for a total value of $1,056,817.68. Following the transaction, the executive vice president owned 48,899 shares of the company’s stock, valued at $6,621,902.58. This represents a 13.76% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Patrick Michael Murphy sold 7,805 shares of the company’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $135.42, for a total value of $1,056,953.10. Following the completion of the transaction, the insider directly owned 60,536 shares in the company, valued at $8,197,785.12. This trade represents a 11.42% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 94,509 shares of company stock worth $12,734,195 over the last ninety days. Corporate insiders own 1.10% of the company’s stock.

Institutional Investors Weigh In On iRhythm Technologies

Several hedge funds have recently made changes to their positions in IRTC. Royal Bank of Canada lifted its holdings in shares of iRhythm Technologies by 423.0% in the 1st quarter. Royal Bank of Canada now owns 7,573 shares of the company’s stock worth $793,000 after buying an additional 6,125 shares during the period. Goldman Sachs Group Inc. lifted its holdings in shares of iRhythm Technologies by 33.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 433,780 shares of the company’s stock worth $45,408,000 after buying an additional 108,941 shares during the period. Strs Ohio purchased a new stake in shares of iRhythm Technologies in the 1st quarter worth $147,000. Arrowstreet Capital Limited Partnership purchased a new stake in shares of iRhythm Technologies in the 2nd quarter worth $1,278,000. Finally, First Trust Advisors LP lifted its holdings in shares of iRhythm Technologies by 66.0% in the 2nd quarter. First Trust Advisors LP now owns 56,197 shares of the company’s stock worth $8,652,000 after buying an additional 22,337 shares during the period.

About iRhythm Technologies

iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company’s flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm’s digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.